What are the highlights of the cooperation between Merck and Sinopharm Holdings in COVID-19?

1. Cooperation content: Merck and Sinopharm Group cooperated to develop COVID-19 oral medicine, which is the first cooperation between them in the treatment field of COVID-19.

2. Significance of cooperation: This cooperation will help promote the treatment process in COVID-19 and provide new weapons for the global fight against the COVID-19 epidemic.

3. Cooperation mode: Merck is responsible for drug research and development and production, and Sinopharm Group is responsible for the promotion and sales in China market.

4. Prospects for cooperation: If this COVID-19 oral drug can be successfully developed and marketed, it will have a great impact on the global fight against the COVID-19 epidemic. At the same time, it will also bring huge business opportunities for Merck and Sinopharm Group.

5. Cooperation risk: Due to the uncertainty in COVID-19, the research, development and marketing of this drug may face great risks. At the same time, many companies in China developed vaccines from COVID-19, which also brought competitive pressure to Merck and Sinopharm.

6. Impact of cooperation: This cooperation may change the global pattern of COVID-19 treatment and have a far-reaching impact on the global fight against the COVID-19 epidemic.